YM598 in Patients With Rising PSA After Initial Therapy for Localized Prostate Cancer

This study has been terminated.
Sponsor:
Collaborator:
Astellas Pharma US, Inc.
Information provided by:
Astellas Pharma Inc
ClinicalTrials.gov Identifier:
NCT00050297
First received: December 3, 2002
Last updated: June 6, 2012
Last verified: June 2012

December 3, 2002
June 6, 2012
Not Provided
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00050297 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
YM598 in Patients With Rising PSA After Initial Therapy for Localized Prostate Cancer
Not Provided

The purpose of this study is to determine the optimal dosage of YM598 for slowing down disease progression in patients with rising PSA after initial therapy for localized prostate cancer.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Prostate Cancer
Drug: YM598
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
Not Provided
February 2004
Not Provided
Not Provided
Male
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Belgium,   Czech Republic,   France,   Germany,   Poland,   Spain,   United Kingdom
 
NCT00050297
598-CL-004
Not Provided
Not Provided
Astellas Pharma Inc
Astellas Pharma US, Inc.
Not Provided
Astellas Pharma Inc
June 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP